Results 1 to 10 of about 169 (159)
Atención Primaria, 2004 The incidence of malignant melanoma in the UK is still rising despite public health warnings about the risks of excessive sun exposure. This aggressive tumour can metastasize to virtually any organ, even years after resection of the primary lesion and cause a variety of radiological appearances.
Casanova Seuma, J.M. +1 more
openaire +4 more sources
Canadian Medical Association Journal, 2019 AbstractCurrent recommendations by the United States Preventive Services Task Force do not support screening for skin cancer. Melanoma is unique among cancers because detection is through visual inspection. Development of technologies that aid visual inspection have supported screening strategies in high‐risk populations such as older fair skinned ...
Robert, Micieli, Kucy, Pon
openaire +4 more sources
Annals of Oncology, 2009 Biomarkers are tumour- or host-related factors that correlate with tumour biological behaviour and patient prognosis. High-throughput analytical techniques--DNA and RNA microarrays--have identified numerous possible biomarkers, but their relevance to melanoma progression, clinical outcome and the selection of optimal treatment strategies still needs to
Gogas, H. +7 more
openaire +3 more sources
Epidemiology of Melanoma [PDF]
Medical Sciences, 2021 Melanoma accounts for 1.7% of global cancer diagnoses and is the fifth most common cancer in the US. Melanoma incidence is rising in developed, predominantly fair-skinned countries, growing over 320% in the US since 1975. However, US mortality has fallen almost 30% over the past decade with the approval of 10 new targeted or immunotherapy agents since ...
Kalyan Saginala +4 more
openaire +4 more sources
Frontiers in Genetics, 2013 Genomic variation is a trend observed in various human diseases including cancer. Genetic studies have set out to understand how and why these variations result in cancer, why some populations are pre-disposed to the disease, and also how genetics affect drug responses. The melanoma incidence has been increasing at an alarming rate worldwide.
Janet Wangari-Talbot, Suzie Chen
openaire +4 more sources
Nihon rinsho. Japanese journal of clinical medicine, 2016 Since 2011, several effective drugs for patients with metastatic melanoma, including the BRAF inhibitors, the MEK inhibitors and the immune checkpoint inhibitors, have been ap- proved. Ipilimumab, nivolumab and the combination have shown response rates of 10-20%, 20-40% and up to 60% and a median progression-free survival of 2, 7 and 12 months, respec-
Arias Santiago, Salvador Antonio +1 more
openaire +5 more sources
Acta Dermato Venereologica, 2017 International ...
S. Veraldi, P. Pontini, F. Sala, D. Tosi
openaire +7 more sources
Melanoma and Immunosuppression [PDF]
Dermatology, 2009 In a recent article, Richtig et al. [1] suggested that immunosuppression may be a risk factor for melanoma development and, in order to support this view, cited a study demonstrating an increased frequency of melanoma in organ transplant recipients receiving long-term immunosuppression [2] .
Belloni Fortina A +4 more
openaire +4 more sources
Cancers, 2015 A tremendous amount of information was published over the past decades in relation to the role of vitamins in various neoplastic diseases. In particular, several studies showed an inverse relationship between selected vitamins intake and cancer risk.
Russo, Irene +2 more
openaire +3 more sources
Immunosurveillance and Melanoma
Journal of Investigative Dermatology, 1989 There is considerable indirect and some direct evidence that immune mechanisms can play an important role in controlling the growth of melanoma. In mice, melanoma can be prevented with vaccines. Consequently, even though naturally occurring immunosurveillance may not be sufficiently potent to prevent melanoma, it is possible that the prophylactic ...
openaire +3 more sources